Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV)

Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), a specialty pharmaceutical company, is focused on the acquisition, development, and commercialization of products designed to treat conditions in urology and endocrinology. The company’s approved products include SANCTURA® and SANCTURA XR(TM) for overactive bladder, SUPPRELIN® LA for central precocious puberty, VANTAS® for advanced prostate cancer, and DELATESTRYL® to treat male hypogonadism. For further information, visit the Company’s web site at www.indevus.com.